Search Results
Your search for The A matches 31900 pages
Showing 4701 - 4750Novel Pembrolizumab-Based Combination Under Study in Metastatic Urothelial Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Sadeghi et al found that EphrinB2 inhibition with soluble EphB4-human serum albumin (sEphB4-HSA) plus pembrolizumab appeared to exert substantial activity in patients with metastatic urothelial carcinoma, particularly among patients...
New Risk Stratification System for Completely Resected Stage II or III Colorectal Cancer
As reported in The Lancet Oncology, Kleppe et al have developed a risk stratification system using the DoMore-v1-CRC marker and pathologic staging markers that may permit many patients with stage II or III colorectal cancer to avoid adjuvant chemotherapy. As stated by the investigators, “The...
Expert Point of View: Ryan B. Corcoran, MD, PhD
Ryan B. Corcoran, MD, PhD, commented on the C-800 study for The ASCO Post. Dr. Corcoran is the Mark J. Kusek Endowed Chair in Colorectal Cancer, Director of the Gastrointestinal Cancer Center Program and Scientific Director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital...
Activity Shown for Novel Immunotherapy Combination in Microsatellite-Stable Colorectal Cancer
Expanded data from the phase I C-800 study showed the immunotherapy combination of botensilimab and balstilimab appeared to be active in patients with microsatellite-stable (MSS) metastatic colorectal cancer. The findings were reported at the European Society for Medical Oncology (ESMO) World...
Durability of Responses to BCMA CAR T-Cell Therapy in Patients With Multiple Myeloma May Depend on Specific Components of the Tumor Microenvironment
Currently, there are two U.S. Food and Drug Administration–approved chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) for adult patients with relapsed or refractory multiple myeloma: idecabtagene vicleucel and citacabtagene autoleucel. However, although ...
New Cervicovaginal Epigenetic Test for Screening of Suspected Endometrial Cancer
As reported in the Journal of Clinical Oncology, Herzog et al have developed a simple noninvasive test for screening for suspected endometrial cancer—the Women’s Cancer Risk Identification-Quantitative Polymerase Chain Reaction Test for Endometrial Cancer (WID-qEC)—that has shown accuracy in...
Addition of T-VEC to Pembrolizumab in Advanced Melanoma
As reported in the Journal of Clinical Oncology by Chesney et al, the phase III MASTERKEY-265 trial has shown no significant improvement in progression-free survival or overall survival with the addition of talimogene laherparepvec (T-VEC) to pembrolizumab in patients with advanced melanoma. Study...
Neoadjuvant Chemotherapy and Organ-Preserving Surgery in Early Rectal Cancer
As reported in the Journal of Clinical Oncology by Hagen F. Kennecke, MD, MHA, and colleagues, the Canadian Cancer Trials Group phase II NEO trial has shown that 3 months of neoadjuvant chemotherapy resulted in tumor downstaging and avoidance of radical surgery in a high proportion of patients with ...
ASTRO Issues Clinical Guideline on Radiation Therapy for IDH-Mutant Glioma
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients with isocitrate dehydrogenase (IDH)-mutant grade 2 and grade 3 diffuse glioma. Evidence-based recommendations outline the multidisciplinary...
Can Patients With Low-Risk Nasopharyngeal Cancer Be Treated Safely With Radiotherapy Alone?
Intensity-modulated radiation therapy (IMRT) alone may be considered an effective treatment option for “low-risk” T1–2N1 and T3N0 nasopharyngeal carcinoma, according to trial data presented by Jun Ma, MD, MS, Professor of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China,...
Cabozantinib Prolongs Progression-Free Survival in Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
As reported in The Lancet Oncology by Marcia S. Brose, MD, Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III COSMIC-311 trial has shown that cabozantinib produced a numerically higher objective response rate and significantly prolonged progression-free survival vs...
Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer
In an interim analysis of the Chinese phase III REALITY trial reported in JAMA Oncology, Lin et al found that apatinib, a highly selective VEGFR2 inhibitor, significantly prolonged progression-free survival vs placebo in patients with progressive, locally advanced or metastatic, radioactive...
FDA Approves Cabozantinib for Patients With Previously Treated Radioactive Iodine–Refractory Differentiated Thyroid Cancer
On September 17, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) for the treatment of adult and pediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth...
Addition of Selumetinib to Adjuvant Radioactive Iodine in High-Risk Differentiated Thyroid Cancer
As reported in the Journal of Clinical Oncology by Ho et al, the phase III ASTRA trial showed no improvement in complete remission rate with the addition of selumetinib to adjuvant radioactive iodine (RAI) in patients with high-risk differentiated thyroid cancer. As stated by the investigators,...
Thyroidectomy With or Without Radioiodine for Low-Risk Thyroid Cancer
In the French phase III ESTIMABL2 trial reported in The New England Journal of Medicine, Leboulleux et al found that no use of radioiodine was noninferior to radioiodine ablation in the occurrence of functional, structural, or biologic events among patients undergoing thyroidectomy for low-risk...
Expert Point of View: Alexander T. Pearson, MD, PhD
Alexander T. Pearson, MD, PhD, Assistant Professor of Medicine at the University of Chicago, commended the artificial intelligence (AI)-augmented, ultrasound-based platform for screening and staging of thyroid cancer. “In this study, Dr. Chan and colleagues processed high-resolution ultrasound...
Study Finds AI Ultrasound Platform Can Predict Thyroid Malignancy, Pathologic Stage, and BRAF Mutation Status
An artificial intelligence (AI) ultrasound platform that incorporates multiple methods of machine learning can accurately predict thyroid malignancy as well as pathologic and genomic outcomes, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Findings from...
First-Line Cisplatin Plus Gemcitabine or Fluorouracil for Advanced Nasopharyngeal Carcinoma: Final Overall Survival Analysis
As reported in the Journal of Clinical Oncology by Hong et al, the final overall survival analysis of the Chinese phase III GEM20110714 trial showed a significant benefit with gemcitabine/cisplatin vs fluorouracil/cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal...
HPV Vaccination and Projected Oropharyngeal Cancer Incidence Through the Year 2045
In a population-based age-period-cohort study reported in JAMA Oncology, Zhang et al estimated that current human papillomavirus (HPV) vaccination rates will have a limited impact on overall oropharyngeal cancer incidence through 2045, due to a high risk of oropharyngeal cancer in unvaccinated...
Primary Transoral Surgery and Reduced-Dose Adjuvant Radiation Therapy for HPV-Positive Locally Advanced Oropharyngeal Cancer
As reported in the Journal of Clinical Oncology by Robert L. Ferris, MD, PhD, and colleagues, the phase II ECOG-ACRIN E3311 trial has shown high progression-free survival rates and good functional outcomes in patients with intermediate-risk human papillomavirus (HPV; p16)-positive locally advanced...
Expert Point of View: Farzan Siddiqui, MD, PhD
“MC1675 is an important and exciting trial,” stated invited discussant Farzan Siddiqui, MD, PhD, of the Henry Ford Cancer Institute, Detroit. “Congratulations to the authors and to Dr. Ma for his award.” “There is strong evidence to suggest that patients with HPV-positive oropharyngeal cancers...
De-escalation of Radiation Therapy for HPV-Positive, Intermediate-Risk Oropharyngeal Cancer
De-escalated adjuvant radiotherapy appears to be safe in patients with surgically resectable, human papillomavirus (HPV)--positive oropharyngeal cancers, particularly in patients without extranodal extension or pN2 disease by American Joint Committee on Cancer (AJCC) 8th edition. These findings...
Radiotherapy Alone vs Concurrent Chemoradiotherapy in Low-Risk Nasopharyngeal Cancer
In a Chinese phase III trial reported in JAMA, Tang et al found that radiotherapy alone was noninferior to concurrent chemoradiotherapy in failure-free survival in patients with low-risk nasopharyngeal carcinoma. Study Details In the open-label multicenter trial, 341 patients were randomly assigned ...
Addition of Chemotherapy to Gefitinib in First-Line Treatment of Advanced NSCLC With EGFR Mutations
In an updated analysis of the Japanese phase III NEJ009 trial reported in the Journal of Clinical Oncology, Miyauchi et al found that gefitinib plus carboplatin/pemetrexed was associated with prolonged progression-free survival and progression-free survival 2—but loss of significance in overall...
Fertility Preservation Measures Do Not Appear to Increase the Risk of Breast Cancer Recurrence
Women with a breast cancer diagnosis undergoing procedures for fertility preservation are not at an increased risk for recurrence of the disease or disease-specific mortality, according to the results of a study from the Karolinska Institutet in Sweden that followed participants for 5 years on...
Prevalence of MGUS Among Rescue and Recovery Workers Exposed to the World Trade Center Disaster
In an observational seroprevalence study reported in Blood Cancer Journal, Zeig-Owens et al found an elevated prevalence of myeloma precursor disease—monoclonal gammopathy of undetermined significance (MGUS)—in a cohort of World Trade Center (WTC) disaster–exposed rescue and recovery workers....
Addition of Galunisertib to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
In a small phase II trial reported in The Lancet Oncology, Yamazaki et al found that the TGF-β type I receptor kinase inhibitor galunisertib appeared to show activity when added to neoadjuvant chemoradiation in previously untreated patients with locally advanced rectal cancer. As stated by the...
Expert Point of View: Quynh-Thu Le, MD, FACR, FASTRO
In an interview with The ASCO Post, Quynh-Thu Le, MD, FACR, FASTRO, Professor and Chair of Radiation Oncology at Stanford Cancer Center, called this phase II de-escalation trial an “intriguing study” that heads in the right direction for treatment de-escalation. However, Dr. Le noted, the...
Midtreatment Imaging De-escalates Therapy for Half of Study Patients With Oropharyngeal Cancer
Positron-emission tomography (PET) scans obtained before and midway through treatment may be used to de-escalate therapy for patients with oropharyngeal cancer, leading to fewer side effects, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 An interim...
Expert Point of View: Quynh-Thu Le, MD, FACR, FASTRO
According to Quynh-Thu Le, MD, FACR, FASTRO, Professor and Chair of Radiation Oncology at Stanford, these results suggest that monitoring circulating human papillomavirus (HPV) DNA may lead to the detection of relapse prior to imaging. In an interview with The ASCO Post, Dr. Le also noted that...
Blood Test Predicts Recurrence of HPV-Driven Oropharyngeal Cancer After Treatment
A blood-basedliquid biopsy may accurately predict recurrence of human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma following treatment, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Results of the large, multi-institutional study...
Do Perioperative Beta-Blockers Improve Survival in Patients With Cardiovascular Conditions Undergoing Surgery for Ovarian Cancer?
In an Australian population–based study reported in the Journal of Clinical Oncology, Spilsbury et al found that perioperative dispensing of nonselective beta-blockers was associated with improved survival among patients with a history of a cardiovascular condition undergoing surgery for epithelial ...
Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil for Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in JAMA Oncology, Li et al found that induction chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) prior to concurrent chemoradiation was associated with improved failure-free survival vs induction therapy with cisplatin and fluorouracil (PF) in...
Expert Point of View: Gary Walker, MD, MPH, MS
Gary Walker, MD, MPH, MS, a head and neck radiation oncologist at Banner MD Anderson Cancer Center, Arizona, expressed concern about the disparities identified in the adoption of advanced radiation therapy techniques for patients with head and neck cancer. “Despite widespread availability of...
Are Disadvantaged Patients Less Likely to Receive Advanced Radiotherapy Techniques for Head and Neck Cancer?
Advanced radiotherapy techniques may reduce the risk of severe and debilitating toxicity associated with radiation, but not all patients have equal access to these modalities, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Retrospective analysis of the...
Tislelizumab Plus Chemotherapy Improves Progression-Free Survival in Nasopharyngeal Cancer
The addition of the checkpoint inhibitor tislelizumab to first-line chemotherapy significantly reduced the risk of disease progression or death by 50% and, despite a 49% crossover rate, numerically boosted overall survival in patients with recurrent or metastatic nasopharyngeal cancer, Zhang et al...
Head and Neck Cancer 2021–2022 Almanac
Head and neck cancer is the seventh most common cancer in the world, with 1.1 million new diagnoses reported annually.1 In the United States, the incidence of oral and pharyngeal cancers is over 54,000 cases per year, resulting in over 11,000 yearly deaths.2 Although smoking and alcohol consumption ...
Study Shows AI May Improve Prediction of Colorectal Cancer Recurrence
In a multinational study using artificial intelligence (AI), investigators developed an algorithm to improve the prediction of colorectal cancer recurrence. Study results were published by Pai et al in Gastroenterology. QuantCRC Rish K. Pai, MD, PhD, a pathologist at Mayo Clinic in Arizona and...
Researchers Outline a Path to Representation in Cancer Clinical Trials
A new study published by Birhiray et al in Blood Advances outlines practical strategies for promoting diversity, equity, inclusion, and access in cancer clinical research. The study highlights significant racial disparities in cancer research, citing that between 2008 and 2018, only 7.8% of...
Cabazitaxel in Advanced Dedifferentiated Liposarcoma
In a phase II EORTC Soft-Tissue and Bone Sarcoma Group trial reported in JAMA Oncology, Sanfilippo et al found that cabazitaxel showed activity in locally advanced, inoperable, or metastatic dedifferentiated liposarcoma. Study Details In the trial, 38 evaluable patients who had received no more...
Chronic Toxicity With Adjuvant Intensity-Modulated vs Conventional Radiation Therapy for Cervical or Endometrial Cancer
As reported in the Journal of Clinical Oncology by Yeung et al, updated results of the phase III NRG Oncology RTOG 1203 trial show reduced chronic toxicity with adjuvant intensity-modulated radiation therapy (IMRT) vs conventional radiotherapy (CRT) in women with cervical or endometrial cancer. No...
Analysis of Outcomes in NCI-Sponsored Phase I Trials in Solid Tumors: 2000–2019
As reported in The Lancet by Chihara et al, analysis of outcomes in National Cancer Institute (NCI)-sponsored, investigator-initiated phase I trials in solid tumors over a 20-year period has shown a near doubling of objective response rate, with no increase in treatment-related mortality. Study...
FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 Rearrangement
On August 26, the U.S. Food and Drug Administration (FDA) approved pemigatinib (Pemazyre), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. Myeloid/lymphoid neoplasms with...
Deep-Learning Algorithm May Streamline Lung Cancer Radiotherapy Treatment
Lung cancer, the most common cancer worldwide, is targeted with radiation therapy in nearly one-half of cases. Radiation therapy planning is a manual, resource-intensive process that can take days to weeks to complete, and even highly trained physicians vary in their determinations of how much...
Researchers Identify Markers of Chemotherapy Resistance and Outcome in Patients With Triple-Negative Breast Cancer
Researchers have identified biological markers in patients with triple-negative breast cancer that are associated with resistance to chemotherapy. The study was published by Anurag et al in the journal Cancer Discovery and was funded by the National Cancer Institute’s Clinical Proteomics Tumor...
Etoposide/Cisplatin vs Irinotecan/Cisplatin in Advanced Digestive System Neuroendocrine Carcinoma
In a Japanese phase III trial (TOPIC-NEC) reported in JAMA Oncology, Morizane et al found no difference in overall survival with etoposide/cisplatin (EP) vs irinotecan/cisplatin (IP) in chemotherapy-naive patients with advanced digestive system neuroendocrine carcinoma. Study Details The open-label ...
Racial/Ethnic Representation in Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma
In a study reported in the Journal of Clinical Oncology, Casey et al found that most U.S. minority populations were underrepresented in clinical trials leading to U.S. Food and Drug Administration approval of drugs for treating leukemias and multiple myeloma. Study Details The investigators...
Clinical and Translational Researcher Rossana Berardi, MD, Works to Overcome the Gender Gap in Oncology in Italy
In our continuing effort to connect and learn more about our international oncology colleagues, The ASCO Post recently spoke with Rossana Berardi, MD, Professor in Medical Oncology and Director of the Postgraduate School of Oncology at the Università Politecnica Marche, Ancona, Italy, where she is...
International Career Joins Cancer Research and Clinical Care of Patients With Lung Cancer
Pilar Garrido, MD, PhD, is Head of the Medical Oncology Department, University Hospital Ramón y Cajal, Madrid. She is also Co-Director of the Cancer Research Group at Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Her main areas of research and clinical interest are thoracic tumors,...
Success Story in Prostate Cancer for Many Men
“I now think of prostate cancer as a story of success for many men, given the advancements in both research and treatment options over the past decade,” Behfar Ehdaie, MD, MPH, told The ASCO Post. Dr. Ehdaie is lead author of a study that found MRI-guided focused ultrasound focal therapy is safe...
